Cadrenal’s CAD-1005 Cuts Thrombotic Events in Phase 2 HIT Ahead of FDA Meeting
Cadrenal Therapeutics’ parenteral CAD-1005 selective 12-LOX inhibitor cut thrombotic events in a blinded, placebo-controlled Phase 2 HIT trial, ahead of an FDA End-of-Phase 2 meeting scheduled this month. The newly acquired 12-LOX portfolio spans oral and parenteral candidates targeting multi-billion-dollar inflammatory and thrombotic disease markets.
1. Encouraging Phase 2 HIT Trial Results
Cadrenal’s parenteral CAD-1005 selective 12-LOX inhibitor reduced thrombotic events on top of standard anticoagulants in a blinded, placebo-controlled Phase 2 study of heparin-induced thrombocytopenia.
2. 12-LOX Inhibitor Portfolio Expansion
The company acquired a portfolio of selective oral and parenteral 12-LOX inhibitors and is exploring applications across atherosclerosis, vascular inflammation, ischemia-reperfusion injury, type 1 diabetes and obesity, representing multi-billion-dollar global markets.
3. Regulatory Milestones and Broader Pipeline
An End-of-Phase 2 meeting with the FDA is scheduled later this month and CAD-1005 holds Orphan Drug and Fast Track designations from the FDA and orphan status from the EMA; the wider pipeline includes Phase 3-ready tecarfarin and parenteral frunexian.